Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRSS1 | P07477 | 4/20 | 0.67 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.67 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.67 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | C1S | P09871 | 1/20 | 0.45 |
| ▸ | F2 | P00734 | 4/20 | 0.44 |
| ▸ | F10 | P00742 | 3/20 | 0.44 |
| ▸ | PLAU | P00749 | 4/20 | 0.44 |
| ▸ | PLG | P00747 | 2/20 | 0.44 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.44 |
| ▸ | KLK1 | P06870 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.43 |
| ▸ | HTR3B | O95264 | 1/20 | 0.43 |
| ▸ | HTR3A | P46098 | 1/20 | 0.43 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.43 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.43 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14099339 | 0.83 | PRSS1 (0.67) | PRSS1PRSS2PRSS3LMNAC1S | |
| Hydrochloric Acid SCHEMBL5125374 | 0.82 | PRSS1 (0.64) | PRSS1PRSS2PRSS3LMNAC1S | |
| SCHEMBL10436207 | 0.80 | LMNA (0.54) | PRSS1PRSS2PRSS3LMNAF2 | |
| SCHEMBL8404520 | 0.80 | PRSS1 (1.00) | PRSS1PRSS2PRSS3LMNAC1S | |
| SCHEMBL1755245 | 0.79 | HPGD (0.51) | CYP3A4HPGDMAPTCHRNA1CHRNG | |
| Hydrochloric Acid SCHEMBL11798099 | 0.78 | LMNA (0.58) | PRSS1PRSS2PRSS3LMNAF2 | |
| Hydrochloric Acid SCHEMBL5118627 | 0.78 | PRSS1 (0.95) | PRSS1PRSS2PRSS3LMNAC1S | |
| Hydrochloric Acid SCHEMBL27585336 | 0.78 | HPGD (0.50) | CYP3A4HPGDMAPTCHRNA1CHRNG | |
| Benzene SCHEMBL9187949 | 0.77 | TSHR (0.54) | PRSS1PRSS2PRSS3LMNAC1S | |
| SCHEMBL395482 | 0.77 | PRSS1 (0.69) | PRSS1PRSS2PRSS3LMNAC1S |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021113698-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION (US) | 2021-06-10 | — | — | WO | disclosed |
| WO-2021113690-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION (US) | 2021-06-10 | — | — | WO | disclosed |
| WO-2021113682-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION (US) | 2021-06-10 | — | — | WO | disclosed |
| WO-2021113686-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION (US) | 2021-06-10 | — | — | WO | disclosed |
| US-20190307737-A1 | NOVEL PIPERIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2019-10-10 | — | — | US | disclosed |
| EP-3227282-B1 | NOVEL PIPERIDINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2019-04-03 | — | — | EP | disclosed |
| US-10172843-B2 | Piperidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2019-01-08 | — | — | US | disclosed |
| US-20170266175-A1 | NOVEL PIPERIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2017-09-21 | — | — | US | disclosed |
| CN-1044809-C | Herbicidal aryl and heteroaryl pyrimidines | SANDOZ LTD (CH) | 1999-08-25 | — | — | CN | disclosed |
| EP-0739341-B1 | HERBICIDAL ARYL AND HETEROARYL PYRIMIDINES | NOVARTIS AG (CH) | 1999-06-02 | — | — | EP | disclosed |
| CN-1138859-A | Herbicidal aryl and heteroaryl pyrimidines | SANDOZ LTD (CH) | 1996-12-25 | — | — | CN | disclosed |
| EP-0739341-A1 | HERBICIDAL ARYL AND HETEROARYL PYRIMIDINES | Novartis AG (CH) | 1996-10-30 | — | — | EP | disclosed |
| WO-1995019358-A1 | HERBICIDAL ARYL AND HETEROARYL PYRIMIDINES | SANDOZ LTD. (CH) | 1995-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190307737-A1 | NOVEL PIPERIDINE DERIVATIVES | ADORA1, ADRA1D, ADORA2B | PRSS1 2802/4885PRSS2 3701/4885PRSS3 3988/4885 |
| US-20170266175-A1 | NOVEL PIPERIDINE DERIVATIVES | ADORA1, ADRA1D, ADORA2B | PRSS1 2802/4885PRSS2 3701/4885PRSS3 3988/4885 |
| US-10172843-B2 | Piperidine derivatives | ADRA1D, ADORA1, ADRA1A | PRSS1 2862/4885PRSS2 3467/4885PRSS3 3563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.